These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33017429)

  • 1. Comparative test-retest variability of outcome parameters derived from brain [18F]FDG PET studies in non-human primates.
    Goutal S; Tournier N; Guillermier M; Van Camp N; Barret O; Gaudin M; Bottlaender M; Hantraye P; Lavisse S
    PLoS One; 2020; 15(10):e0240228. PubMed ID: 33017429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG.
    Hahn A; Gryglewski G; Nics L; Hienert M; Rischka L; Vraka C; Sigurdardottir H; Vanicek T; James GM; Seiger R; Kautzky A; Silberbauer L; Wadsak W; Mitterhauser M; Hacker M; Kasper S; Lanzenberger R
    J Nucl Med; 2016 Dec; 57(12):1933-1940. PubMed ID: 27390156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using 18F-FDG PET/CT.
    Gheysens O; Postnov A; Deroose CM; Vandermeulen C; de Hoon J; Declercq R; Dennie J; Mixson L; De Lepeleire I; Van Laere K; Klimas M; Chakravarthy MV
    J Nucl Med; 2015 Oct; 56(10):1520-6. PubMed ID: 26229142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test-Retest Stability of Cerebral 2-Deoxy-2-[
    Sijbesma JWA; van Waarde A; Vállez García D; Boersma HH; Slart RHJA; Dierckx RAJO; Doorduin J
    Mol Imaging Biol; 2019 Apr; 21(2):240-248. PubMed ID: 29987619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of parametric K
    Wu J; Liu H; Ye Q; Gallezot JD; Naganawa M; Miao T; Lu Y; Chen MK; Esserman DA; Kyriakides TC; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5219-5231. PubMed ID: 34287939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with (18) F-FDG: exemplified in a memantine pharmacological challenge.
    Deleye S; Verhaeghe J; wyffels L; Dedeurwaerdere S; Stroobants S; Staelens S
    Neuroimage; 2014 Aug; 96():276-87. PubMed ID: 24736171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents.
    Schiffer WK; Mirrione MM; Dewey SL
    J Nucl Med; 2007 Feb; 48(2):277-87. PubMed ID: 17268026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
    J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
    Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
    J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards quantitative [18F]FDG-PET/MRI of the brain: Automated MR-driven calculation of an image-derived input function for the non-invasive determination of cerebral glucose metabolic rates.
    Sundar LK; Muzik O; Rischka L; Hahn A; Rausch I; Lanzenberger R; Hienert M; Klebermass EM; Füchsel FG; Hacker M; Pilz M; Pataraia E; Traub-Weidinger T; Beyer T
    J Cereb Blood Flow Metab; 2019 Aug; 39(8):1516-1530. PubMed ID: 29790820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
    Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography.
    Toyama H; Ichise M; Liow JS; Modell KJ; Vines DC; Esaki T; Cook M; Seidel J; Sokoloff L; Green MV; Innis RB
    J Nucl Med; 2004 Aug; 45(8):1398-405. PubMed ID: 15299067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach.
    Busk M; Munk OL; Jakobsen S; Frøkiær J; Overgaard J; Horsman MR
    Acta Oncol; 2017 May; 56(5):706-712. PubMed ID: 28094665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
    J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test-Retest Repeatability of Patlak Slopes versus Standardized Uptake Values for Hypermetabolic Lesions and Normal Organs in an Oncologic PET/CT Population.
    Ince S; Laforest R; Ashrafinia S; Smith AM; Wahl RL; Fraum TJ
    Mol Imaging Biol; 2024 Apr; 26(2):284-293. PubMed ID: 38466523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.
    Shankar LK; Huang E; Litiere S; Hoekstra OS; Schwartz L; Collette S; Boellaard R; Bogaerts J; Seymour L; deVries EGE
    Clin Cancer Res; 2023 Jan; 29(1):143-153. PubMed ID: 36302172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.